For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

A method for slowing disease progress in Alzheimer's patients may also delay onset in people predisposed to the disease who ...

A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...

《Molecular Neurobiology》：The HDL-Mimetic Peptide 4F Mitigates Vascular and Cortical Amyloid Pathology and Associated Neuroinflammation in a Transgenic Mouse Model of Cerebral Amyloid Angiopathy and ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

The probiotic-rich drink kefir may be a potential complementary treatment for Alzheimer’s disease by helping improve ...

Alzheimer's Disease can seem like a tragic inevitability for those who have rare genetic forms of the disease. The ...

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

A comprehensive Thought Leaders Invited Review in Brain Medicine highlights the crucial role of CD2-associated protein (CD2AP ...

A recent trial on gantenerumab showed that the drug could reduce the risk of Alzheimer’s symptoms by 50% in pre-symptomatic ...

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...